Drug Trial Radar · NCT00347932
A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.
Last checked: Nov 20, 2026Latest source record: Mar 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
957
Actual
Start
Jun 2006
Primary completion
Nov 2007
Study completion Nov 2007
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jul 4, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis.
Conditions
- Acute Bacterial Conjunctivitis
Interventions
ISV-403Drug
Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
VehicleDrug
Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Resolution of Baseline Bacterial ConjunctivitisTime frame: Day 5 +/- 1 day
- Microbial Eradication of Baseline Bacterial InfectionTime frame: Day 5 +/- 1 day
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.